CCL17 and Myocardial fibrosis: Compared with IgG controls, CCL17 antibody-treated mice exhibited remarkable attenuation of the Ang II–induced cardiac dysfunction, increases in the myocyte area, and myocardial fibrosis (Fig. 5, C–F).